Menu Back toSession 7 Track 2: RNA Activation

DIA/FDA Oligonucleotide-Based Therapeutics Conference

DIA Your Way! Join us live in-person or live from the comfort of your home/office. This event offers two learning avenues depending on your preference!

Session 7 Track 2: RNA Activation

Session Chair(s)

Patrik  Andersson, PhD

Patrik Andersson, PhD

  • Principal Scientist, Discovery Safety Specialist
  • AstraZeneca R&D, Sweden
Imran  Khan, PhD

Imran Khan, PhD

  • Pharmacologist, OMPT, OND, ODEI, DPP, CDER
  • FDA, United States
A rapidly evolving area for nucleotide based medicines is upregulation of protein for treatment of a wide range of disease types. This session will cover mechanisms, delivery and some unconventional nonclinical studies for three different platforms. You will learn about two different approaches that induce expression of target mRNA for treatment of cancer and Dravet syndrome as well as therapeutic application of mRNA expressing VEGF for treatment of heart failure.
Learning Objective : At the conclusion of this session, participants should be able to:
  • Compare different strategies to treat disease via protein upregulation
  • Define key points to consider for nonclinical development of these platforms
  • Recognize the need for unconventional nonclinical programs for novel approaches


Nagy  Habib, MD, PhD

MTL-CEBPA Transcriptional Level Changes in Machinery

Nagy Habib, MD, PhD

  • Head of Research and Development
  • MiNA Therapeutics Limited , United Kingdom
Anna  Collén, PhD

AZD8601, VEGF mRNA for Cardiac Regeneration

Anna Collén, PhD

  • Global Project Leader, Early Cardiovascular, Renal and Metabolism
  • AstraZeneca, Sweden
Meena  Meena, PhD

Targeted Augmentation of Nuclear Gene Output (TANGO) Technology for Upregulating Target Protein Expression

Meena Meena, PhD

  • VP of Bioanalytical, DMPK and Biomarker Development
  • Stoke Therapeutics, United States